Although the once-weekly schedule offers considerable flexibility, several individual factors may influence the most appropriate timing for each person
GLP-1 medications do more than help with weight lossthey can meaningfully improve cholesterol levels and triglycerides, reducing your overall cardiovascular risk
Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide
Retatrutide has produced some of the strongest weight loss results seen so far in obesity medicine trials
(a ) GIPR IC 50 and GLP-1R EC 50 are comparable with both molecules, despite different GLP-1 analogs used
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
